This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schwartz GG et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718
Cannon CP et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504
Nissen SE (2004) High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 292: 1365–1367
Ridker PM et al. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557–1565
Acknowledgements
The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
SE Nissen receives research support and is a consultant to Pfizer Inc., Sanofi-Aventis Group, Sankyo Pharma Inc., Takeda Ltd., Astra Zeneca, Atherogenics Inc., Eli Lilly and Company and Lipid Sciences Inc.. In addition, SE Nissen is a consultant for GlaxoSmithKline Inc., Forbes Medi-Tech Inc., Novartis, Haptoguard, Novo-Nordisk and Vasogenix Pharmaceuticals Inc.
Rights and permissions
About this article
Cite this article
Nissen, S. Does intensive statin therapy lower mortality and cardiovascular event risk in patients with acute coronary syndrome?. Nat Rev Cardiol 2, 10–11 (2005). https://doi.org/10.1038/ncpcardio0066
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0066